Stock OGN ORGANON & CO.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Organon & Co.

Equities

OGN

US68622V1061

Market Closed - Nyse
Other stock markets
 21:00:02 26/04/2024 BST 		5-day change 1st Jan Change
18.55 USD +0.71% Intraday chart for Organon & Co. +4.10% +28.64%
04-09 Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating MT
04-08 Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
BU
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
BU
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health
AQ
Organon Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs, Replacing HUMIRA on Its National Formulary
AQ
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
BU
Organon Launches U.S. Grant Programs and Listening Tour as Part of "Her Plan Is Her Power," Reaching High-Need Communities To Help Reduce Unplanned Pregnancies
AQ
Organon: Q4 Earnings Snapshot
AQ
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
BU
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
BU
Organon's XACIATO Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older
AQ
Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
BU
Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
BU
Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference
BU
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
BU
Organon To Present at the Piper Sandler 35th Annual Healthcare Conference
BU
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®
AQ
Organon: Q3 Earnings Snapshot
AQ
Organon Reports Results for the Third Quarter Ended September 30, 2023
BU
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
BU
Organon Canada Announces Availability of a High-Concentration, Citrate-Free Formulation of HADLIMA®, a Biosimilar to HUMIRA*
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OGN Stock
  4. News Organon & Co.
  5. Press Releases